The effect of 17 alpha-hydroxyprogesterone caproate/oestradiol valerate on the development and outcome of early pregnancies following in vitro fertilization and embryo transfer: a prospective and randomized controlled trial.
A prospective and randomized study was performed to investigate the effect of supportive hormones on the development and outcome of early pregnancies following in vitro fertilization and embryo transfer. Immediately after pregnancies were confirmed endocrinologically on day 15 after oocyte collection, 17 alpha-hydroxyprogesterone caproate and oestradiol valerate (PC/EV) was administered to half of the patients in a randomly controlled trial. One group received supportive treatment until the twelfth week of gestation, whereas the other group received no treatment at all. Both groups were followed up by measurements of serum levels of human chorionic gonadotrophin (HCG), oestradiol and progesterone every three days until day 35, when a first ultrasound examination was carried out to confirm fetal vitality. Subsequently, pregnancies were monitored sonographically at regular intervals. In cases of miscarriage, dilatation and curettage was performed and histology analysed. A total of 120 pregnant patients entered the study: 55 of them received hormone treatment and 65 patients were controls. Within the treatment group 48 (89%) clinically ongoing pregnancies were observed, five (9%) miscarriages occurred after the seventh week of gestation and one preclinical pregnancy was noted. In the control group, 38 (59%) ongoing pregnancies were observed, nine (14%) miscarriages occurred and 17 (27%) preclinical pregnancies were recorded. Two ectopic pregnancies, one in each group, were excluded from evaluation. A significantly higher percentage of pregnancies were intact at 7 weeks of gestation after treatment with PC/EV (p less than or equal to 0.01).
Prietl
G
G
Department of Obstetrics and Gynaecology, University of Bonn, Germany.
Diedrich
K
K
van der Ven
H H
HH
Luckhaus
J
J
Krebs
D
D
D000077713:17 alpha-Hydroxyprogesterone Caproate; D000328:Adult; D004624:Embryo Transfer; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology*; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D006908:Hydroxyprogesterones / Q000494:pharmacology; D011247:Pregnancy / Q000187:drug effects*; D011256:Pregnancy Outcome; D045167:Progesterone Congeners / Q000494:pharmacology; D011372:Progestins / Q000494:pharmacology*; D011446:Prospective Studies; D012189:Retrospective Studies
D004966:Estrogens, Conjugated (USP); D006908:Hydroxyprogesterones; D045167:Progesterone Congeners; D011372:Progestins; D000077713:17 alpha-Hydroxyprogesterone Caproate; D004958:Estradiol